Now that the FDA has finally approved the first-ever pharmaceutical derived from the cannabis plant, will drug development — and success — in this niche finally take off?
In Germany, bioclusters and technology parks have been created to encourage and support pharmaceutical innovation in the region.
Real-world evidence is playing an increasingly important role throughout the drug development lifecycle—as outlined in Deloitte's latest survey on the life sciences industry's RWE capabilities— and companies are really beginning to take notice.
An in-depth look at J&J’s QuickFire Challenge program and how some of the winners have benefitted (and grown) beyond the cash grants.
Can a culture with supporting systems that are simple, efficient, and effective significantly shorten drug development times? Why not?
A look at a unique UK-based public-private partnership (P3), called Open Targets that was created to help companies choose better drug targets and reduce attrition of candidate drugs.
With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.
GSK is looking to create a more efficient drug development system by integrating AI into its process.
As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.
Ask life sciences industry leaders and experts about blockchain and you will hear it called everything from “a game changer” to “a major disrupter.” According to the hype, the technology behind cryptocurrencies, like bitcoin, is going to completely transform day-to-day operations for life sciences companies.